2025.05.24 (토)

  • 구름많음동두천 17.6℃
  • 맑음강릉 20.3℃
  • 구름많음서울 18.2℃
  • 맑음대전 18.5℃
  • 맑음대구 19.0℃
  • 맑음울산 20.0℃
  • 맑음광주 18.4℃
  • 맑음부산 19.1℃
  • 맑음고창 18.4℃
  • 맑음제주 21.3℃
  • 구름많음강화 15.3℃
  • 구름조금보은 17.3℃
  • 맑음금산 18.1℃
  • 맑음강진군 18.7℃
  • 구름조금경주시 20.7℃
  • 맑음거제 19.7℃
기상청 제공

경제

Moberg Pharma and Menarini Extend Distribution Agreement for Kerasal Nail to South East Asia

[By NBC-1TV H. J Yook]Moberg Pharma AB (OMX: MOB) and Menarini Asia-Pacific, a member of the Menarini Group are pleased to announce that Menarini Asia-Pacific has been granted the exclusive rights to market and sell Kerasal Nail™ in eight Southeast Asian countries.

The extended distribution agreement builds on an existing collaboration between the two company groups, which resulted in a successful launch of the product in Italy and a previous extension of the distribution agreement for China. In Asia-Pacific, Menarini is a leading regional biopharmaceutical company with over 3500 employees in 13 markets and a strong track record in launching and promoting Consumer Health brands. The global sales of the Menarini Group exceed 3 billion Euros.

The extension includes eight Southeast Asian countries: Singapore, Taiwan, Indonesia, Philippines, Malaysia, Hong Kong, Thailand and Vietnam. The added countries represents a market of more than 550 million people in one of the fastest growing regions in the world and represent a significant long term growth opportunity for Moberg Pharma. According to IMS[1], 45% of the global growth in self-medication up to 2016 will come from China and Southeast Asia.

“I am very pleased to announce this agreement which meets one of our targets for 2014 - to enter the rapidly expanding Southeast Asian market. We enter this exciting opportunity together with Menarini Asia-Pacific - an ideal partner in the region. The region has huge potential and the agreement will contribute to revenues and earnings already in 2014,” said Peter Wolpert, CEO of Moberg Pharma AB.

“We look forward to introducing Kerasal Nail™ to consumers in Southeast Asia. The product has potential to contribute strongly to our expansion within the Consumer Health market, being a compelling non-prescription product offering rapid visual improvement and an effective solution for patients with nail fungus problems,” said John A. Graham, CEO at Menarini Asia-Pacific.



배너

관련기사


배너
배너
배너
배너
배너
배너
배너
배너
배너
배너
배너
배너